BROMHEXINE HYDROCHLORIDE Elixir

Bromhexine Hydrochloride creates an environment in the bronchial tree conductive to the removal of sticky mucus, thus promoting expectoration without excessive straining. Bromhexine Hydrochloride is valuable in those conditions of the upper and lower respiratory tract which are associated with retention of viscid mucoid secretions - e.g. Bronchitis, Asthma with or without Bronchitis, Bronchiectasis, Lung Abscess, Emphysematous Bronchitis, Pulmonary Tuberculosis, Industrial Pneumoconioses, Sino-bronchial syndrome (sinusitis complicating bronchitis and vice versa), Bromhexine Hydrochloride should be supplemented with appropriate therapeutic measures for treating infection or bronchospasm, whenever necessary.

Dosage and Administration

Adults: 10-20mL of Elixir 3-4 times daily depending on the severity or chronicity of clinical condition.

Children (5-10 years): 5mL of Elixir 4 times daily.

Children (under 5 years): 5mL of Elixir twice daily.

There are no absolute contra-indications to the use of Bromhexine-Hydrochloride.

BROMHEXINE

Central Nervous System Effects: Dizziness and headache have been associated with bromhexine therapy in some patients. Dizziness has responded to dose reduction.

Gastrointestinal Effects: Nausea, epigastric pain, vomiting, and diarrhea have been reported occasionally during bromhexine therapy. Although infrequent, these adverse effects have necessitated withdrawal of therapy in some patients.

Kidney/Genitourinary: Enuresis (with or without diarrhea) necessitated discontinuation of bromhexine therapy in 3% of children with otitis media in 1 study. However, it is unclear if this effect was definitely attributable to bromhexine.

Liver: Transient elevations in serum aspartate aminotransferase (SGOT) levels have been described infrequently on bronchial glands as opposed to hepatic dysfunction.

Skin: Rarely, skin rash has been reported in bromhexine-treated patients.

There have been no reports of overdosage with Bromhexine Hydrochloride.

Animal studies have not revealed any teratogenic potential of Bromhexine Hydrochloride but its use in the first trimester of pregnancy should be avoided.

Patients with a history of gastric ulceration should be carefully assessed and observed during Bromhexine Hydrochloride treatment.

Bromhexine Hydrochloride has been administrated to have simultaneous physiological and biochemical role in actively aiding expectoration.

Bromhexine Hydrochloride, firstly, increases sputum volume by stimulating the mucous glands of the respiratory tract and by, promoting ciliary clearance of sputum.

Bromhexine Hydrochloride, further, reduces sputum viscosity by breaking down the tenacious network of acid mucopolysaccharide fibres that abound in mucoid spupum and which are mainly responsible for sputum stickiness.